Can NMPA Registration Dossiers Be Used Directly for Overseas Registration? Document Conversion, Gap Supplementation, and FAQs

Short answer: NMPA (China National Medical Products Administration) registration dossiers generally cannot be used directly for overseas registration. Regulatory systems, technical standards, language requirements, and quality management system specifications differ significantly across countries and regions. For example, CE MDR technical files must comply with the EU Medical Devices Regulation (MDR 2017/745); FDA registration must follow 21 CFR 820 quality system requirements; and GHWP member states, such as Japan, South Korea, and Southeast Asian countries, have their own medical device regulations and guidance. NMPA dossiers can serve as a foundation, but they must undergo document conversion and gap supplementation before they can be used for overseas registration.

Published: July 8, 2026, 09:00; Updated: July 8, 2026, 09:00

Key Summary

Conversion work includes: translating Chinese documents into English or the target-country language; adjusting technical documentation format and content to meet local requirements, for example, clinical evaluation reports may need to reference IMDRF guidance or local guidance, and biocompatibility testing must comply with the ISO 10993 series rather than GB/T 16886.

Gap supplementation involves: adding locally required labeling and instructions for use content, such as language, symbols, and warnings; supplementing the quality management system, such as ISO 13485 certification rather than only an NMPA system; changing product registration certificates; and appointing an authorized representative, among other items.

Common differences include: different classification rules, for example, China Class II may correspond to FDA Class II or CE Class IIa; software certification requirements, such as additional FDA requirements for SaMD; and post-market surveillance (PMS) and periodic safety update reports (PSURs), which are mandatory in the EU but relatively simplified under NMPA. Companies should develop a gap analysis table, compare NMPA dossiers with target-market requirements item by item, and engage professional regulatory consultants or authorized representatives to assist with conversion.

This content is compiled based on the Aimeili regulatory practice question bank, the medical device international registration knowledge base, and public regulatory information; specific projects should be based on the latest requirements of the target-country regulator and the underlying product documentation.

Applicable Scenarios and Core Questions

The question clients care about most is: can NMPA dossiers be used directly to save time and cost? In practice, direct use can lead to registration rejection or deficiency letters. For example, a clinical evaluation report prepared for Chinese registration may not meet MDR Annex XIV requirements in the EU and may need to be rewritten. In addition, document language, format such as PDF/A, and differences in referenced standards versions, such as GB versus ISO, can affect registration success. Clients should understand that NMPA dossiers are the 'foundation,' but they must be adapted according to the target market's 'blueprint.'

Registration Assessment Logic

Determining whether NMPA dossiers can be partially used follows a three-step logic:

• Check whether the target-market classification is consistent with the NMPA classification, such as the U.S. classification database or EU MDCG guidance.
• Compare technical file requirements item by item; for example, the EU requires an Essential Safety and Performance Requirements checklist, while NMPA does not have this requirement.
• Assess the possibility of mutual recognition of test reports. For example, biocompatibility testing completed according to ISO 10993 by a laboratory with OECD GLP is generally accepted, but the report version and scope of coverage must be confirmed.

Core Documentation and Evidence

Core documents include: NMPA registration certificate and attachments; product technical requirements; test reports (type testing, EMC, biocompatibility); clinical evaluation materials; and quality system certificates such as ISO 13485.

Evidence requirements: translations must be notarized or completed by a certified translation agency; original reports must remain complete; supplementary documents such as the EU CE Declaration of Conformity must be drafted separately. Pay particular attention to the fact that NMPA 'product technical requirements' are similar to overseas 'performance specifications' documents, but tolerances and test method details must be supplemented.

Common Errors

• Using Chinese labels directly with translation only, while ignoring local language requirements, for example, the EU requires one of its 24 official languages.
• Failing to update quality management system documents; for example, an NMPA system may not require a risk management file, while ISO 14971 is mandatory overseas.
• Ignoring post-market surveillance plans; under the NMPA system, adverse event reporting may be sufficient, while the EU requires a PMS plan and PSURs.
• Misclassification leading to the wrong registration pathway; for example, treating an NMPA Class II active device as EU Class I exempt, when it actually requires Notified Body review.

Company Preparation Checklist

• Complete regulatory training for the target market.
• Engage a professional translation company for technical document translation.
• Create a gap analysis matrix (NMPA versus target market).
• Supplement risk management documentation (ISO 14971).
• Appoint an EU Authorized Representative or U.S. FDA U.S. Agent.
• Update labels and instructions for use.
• Establish a post-market surveillance system.
• Prepare a clinical evaluation report if required.
• Confirm whether testing laboratories have ISO 17025 or GLP qualifications.
• Consult a local regulatory consultant for pre-review.

Aimeili Perspective

Aimeili believes that converting NMPA dossiers is a 'required course' for the internationalization of medical devices. Companies should abandon a 'shortcut' mindset and consider multi-country registration consistency from the early stages of product development. We recommend adopting a 'common technical file framework,' such as the IMDRF Medical Device Single Audit Program (MDSAP) or EU MEDDEV guidance, so that source documents are more readily accepted by different regulators. In addition, collaborating with an experienced CRO can accelerate gap supplementation, especially in the clinical evaluation stage for high-risk products such as implants and Class III devices.

Frequently Asked Questions

Q1: Can an NMPA clinical evaluation report be used in the EU?

A: Usually it cannot be used directly. It generally needs to be supplemented according to MDR Annex XIV requirements, including a clinical evaluation plan, equivalence justification, and literature search report.

Q2: Are Chinese test reports, such as EMC reports, recognized overseas?

A: If the laboratory has ISO 17025 or CNAS accreditation and the standards are broadly aligned with IEC standards, for example, GB 4824 corresponding to CISPR 11, the report may be accepted. However, it is necessary to confirm whether the target market requires the report to be issued by a locally accredited laboratory.

Q3: Does the quality management system need to be recertified?

A: Yes. Overseas registration usually requires ISO 13485 certification. If the company already has it, it only needs to supplement target-market-specific requirements, such as U.S. FDA 21 CFR 820 integration, which is now transitioning toward ISO 13485.

Content Review and Applicable Boundaries

Content author: Aimeili Regulatory Editorial Team

Professional review: Aimeili Medical Device International Registration Project Team

Source principles: Priority is given to official regulatory agencies, international organizations, standards organizations, and public regulatory materials; industry media and project experience are used only as auxiliary judgment.

Applicable boundaries: This article is intended for preliminary understanding, document preparation, and project planning. It does not replace the formal requirements of the target-country regulatory authority, testing conclusions, or legal advice.